Da Vinci Laboratory Solutions accelerates growth through acquisition of JSB
Amsterdam, April 10, 2024 –Our portfolio company Da Vinci Laboratory Solutions (Da Vinci) is acquiring industry peer JSB. Da Vinci and JSB are two well-established companies in the international analytical chemistry market with a focus on chromatography. With the unification of Da Vinci and JSB, Da Vinci strengthens its position as a leading player in the field of knowledge-intensive total solutions in chromatography in the Benelux and beyond.
Developer of specialized chromatography solutions
Da Vinci and JSB operate as suppliers of analytical systems to laboratories, specifically based on chromatography and mass spectrometry. Within these niche markets, Da Vinci and JSB are known as knowledge-intensive companies, delivering added value based on systems from the publicly traded American company Agilent Technologies. Specifically, Da Vinci and JSB integrate chromatography systems with in-house developed and third-party systems to provide a customized total solution to the customer. Around these custom-made chromatography systems, both companies provide consumables as well as technical maintenance and installation services.
Joining forces
The chromatography market is subject to growing customer demand for increasingly complex and sensitive measurements. This desire from customers requires continuous technological development and product knowledge from companies such as Da Vinci and JSB. The unification of Da Vinci and JSB brings together two complementary product and service portfolios, enabling the combination to meet this customer demand even better. The acquisition also strengthens Da Vinci’s international footprint with an office in the United Kingdom, in addition to already existing international offices in India, China and Singapore.
In his new role, Sander Affourtit, COO of JSB, will become the operational director of the merged value-added partners of Agilent: “This increase in scale provides synergy for both parties knowledge and expertise can be shared, thus generating additional strength. Since the product package is complementary, more high-end chromatographic solutions will also become available through the combination.”
Martijn van Raalte CEO Da Vinci, “This merger enables us to create synergies, offer more innovative solutions, provide broader services and better meet the specific needs of our customers in various sectors.”
Philip Wilms, Investment Director Holland Capital, “The acquisition of JSB is an important step in the inorganic growth trajectory of Da Vinci. The market in which both companies operate is international, and having combined the two leading Benelux players we now aim to also expand this acquisition path internationally.”
About JSB
Since 2002 JSB has been active on the Benelux market as a full knowledge partner in chromatographic and mass spectrometric solutions. JSB is one of Agilent’s larger partners in the Netherlands and adds value on the Agilent systems by integrating these systems with complementary modules (e.g., sample preparation and detection equipment) to provide a customized solution for customers. JSB has 19 employees and has offices in Lelystad, Eindhoven and in the UK.
About Da Vinci Laboratory Solutions
Da Vinci Laboratory Solutions was founded as a service provider within the laboratory industry in 2000. Since then Da Vinci has grown to become the versatile partner for laboratories by offering chromatographic solutions for all analytical challenges from sample preparation, analysis, reporting, data management, consumables and technical support. Like JSB, Da Vinci is a value-added reseller of Agilent Technology. Da Vinci has offices in Rotterdam (HQ), Geleen, India, China and Singapore. The company has 50 employees and offers an extensive application and test laboratory, training room and R&D facilities. Da Vinci’s mission is to increase laboratory efficiency with its chromatographic solutions.
About Holland Capital
Holland Capital has been investing responsibly and successfully in promising Dutch and German SMEs with growth ambitions for over 40 years. The team understands entrepreneurship and pursues an open, sustainable and professional relationship with the management teams of the companies in which it invests, with the common goal of achieving growth. Holland Capital has offices in Amsterdam and Düsseldorf. With specialized sector teams it concentrates on the Healthcare, Technology and the recently added focus area Agrifood-Tech. It knows the dynamics and opportunities in these sectors and has a broad network. Holland Capital has been involved in Da Vinci as a shareholder since October 2022. She actively supports the organization in both the operational and strategic development of the company.
Supermetrics acquires leading CDP, Relay42 to redefine the future of Marketing Intelligence
Our portfolio company Relay42, a leading real-time Customer Data Platform (CDP), has been acquired by Supermetrics, the leading Marketing Intelligence Platform. Holland Capital actively supported Relay42 in both operational and strategic development since becoming a shareholder in 2015.
Award-winning design studio flora&faunavisions joins The Storytelling Company
Our portfolio company The Storytelling Company adds the award-winning Berlin-based visual design studio flora&faunavisions to its portfolio of groundbreaking businesses
Holland Capital takes on the Alps for ‘Kinderen van de Voedselbank’ Foundation
This year, a group of sporty colleagues from Holland Capital are taking on a heroic challenge: the Marmotte – one of the toughest and most iconic cycling tours in the French Alps.
Insights from Holland Capital and Deloitte’s webinar
Last week, in partnership with Deloitte, we hosted an engaging and inspiring ESG webinar for our portfolio companies.
Gullimex attracts investor Holland Capital for further growth
Investment firm Holland Capital is investing in Gullimex, a strong player in measurement, quality, and control solutions within the food and medical sectors. Holland Capital’s investment provides Gullimex the opportunity to realize its growth ambitions.
Our portfolio company Sirius Medical is partnering with Mammotome
Our portfolio company Sirius Medical, the innovator of Surgical Marker Navigation and Mammotome, a globally recognized leader in breast care, are proud to announce an exclusive distribution agreement for the United States and Germany.

Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Königsallee 42
40212 Düsseldorf
+49 (0) 211 96290120
Contact
info@hollandcapital.nl